Unknown

Dataset Information

0

Fluorescent visualization of Src by using dasatinib-BODIPY.


ABSTRACT: Many biological experiments are not compatible with the use of immunofluorescence, genetically encoded fluorescent tags, or FRET-based reporters. Conjugation of existing kinase inhibitors to cell-permeable fluorophores can provide a generalized approach to develop fluorescent probes of intracellular kinases. Here, we report the development of a small molecule probe of Src through conjugation of BODIPY to two well-established dual Src-Abl kinase inhibitors, dasatinib and saracatinib. We show that this approach is not successful for saracatinib but that dasatinib-BODIPY largely retains the biological activity of its parent compound and can be used to monitor the presence of Src kinase in individual cells by flow cytometry. It can also be used to track the localization of Src by fixed and live-cell fluorescence microscopy. This strategy could enable generation of additional kinase-specific probes useful in systems not amenable to genetic manipulation or could be used together with fluorescent proteins to enable a multiplexed assay readout.

SUBMITTER: Vetter ML 

PROVIDER: S-EPMC4130483 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Fluorescent visualization of Src by using dasatinib-BODIPY.

Vetter Michael L ML   Zhang Zijuan Z   Liu Shuai S   Wang Jinhua J   Cho HaeYeon H   Zhang Jianming J   Zhang Wei W   Gray Nathanael S NS   Yang Priscilla L PL  

Chembiochem : a European journal of chemical biology 20140514 9


Many biological experiments are not compatible with the use of immunofluorescence, genetically encoded fluorescent tags, or FRET-based reporters. Conjugation of existing kinase inhibitors to cell-permeable fluorophores can provide a generalized approach to develop fluorescent probes of intracellular kinases. Here, we report the development of a small molecule probe of Src through conjugation of BODIPY to two well-established dual Src-Abl kinase inhibitors, dasatinib and saracatinib. We show that  ...[more]

Similar Datasets

| S-EPMC9687994 | biostudies-literature
| S-EPMC10160240 | biostudies-literature
| S-EPMC4416427 | biostudies-literature
| S-EPMC5530629 | biostudies-literature
| S-EPMC4679708 | biostudies-literature
| S-EPMC4683377 | biostudies-literature
| S-EPMC5661875 | biostudies-literature
| S-EPMC7255627 | biostudies-literature
| S-EPMC8164657 | biostudies-literature
| S-EPMC9581486 | biostudies-literature